Literature DB >> 7622907

Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity.

N L Opstad1, C L Daley, J R Thurn, J B Rubins, C Merrifield, P C Hopewell, E N Janoff.   

Abstract

To determine whether defects in mucosal immunity were associated with invasive disease caused by a mucosal pathogen, Streptococcus pneumoniae, levels of salivary immunoglobulins and nonspecific immune factors were compared in subjects with human immunodeficiency virus type 1 (HIV-1) infection and in HIV-1-seronegative subjects with and without pneumococcal bacteremia. The IgA2 subclass may be of particular importance because S. pneumoniae produces IgA1 protease, which cleaves IgA1 but not IgA2. Levels (37-56 micrograms/mL) and proportions (11%-17%) of IgA2 were similar among groups. Serotype-specific capsular salivary IgA was present in a minority of patients with acute bacteremia. Levels of lactoferrin were increased with bacteremia. Neither selective mucosal IgA2 deficiency nor impaired nonspecific upper respiratory mucosal responses were associated with invasive pneumococcal disease during HIV-1 infection; thus, other defects in mucosal cellular responses and systemic immunity may predispose HIV-1-infected patients to invasive pneumococcal disease.

Entities:  

Mesh:

Year:  1995        PMID: 7622907     DOI: 10.1093/infdis/172.2.566

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

2.  Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.

Authors:  S M Wahl; P Worley; W Jin; T B McNeely; S Eisenberg; C Fasching; J M Orenstein; E N Janoff
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

3.  Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes.

Authors:  E N Janoff; C Fasching; J M Orenstein; J B Rubins; N L Opstad; A P Dalmasso
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

4.  Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

Authors:  Jun-Young Seo; Seung Yong Seong; Byung-Yoon Ahn; Ick Chan Kwon; Hesson Chung; Seo Young Jeong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.

Authors:  S Y Seong; N H Cho; I C Kwon; S Y Jeong
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

6.  Pneumococcal IgA1 protease subverts specific protection by human IgA1.

Authors:  E N Janoff; J B Rubins; C Fasching; D Charboneau; J T Rahkola; A G Plaut; J N Weiser
Journal:  Mucosal Immunol       Date:  2013-07-03       Impact factor: 7.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.